Cagrilintide Half-Life: What Human Pharmacokinetic Studies Report
Direct answer: In a published Phase 1b study, cagrilintide had a terminal half-life of 159–195 hours, or roughly 6.6–8.1 days. A later study protocol summarized the value as approximately 180 hours. These measurements describe the tested clinical material and study conditions; they do not establish the behavior of every cagrilintide sample.
Cagrilintide is a long-acting amylin analogue. Its pharmacokinetic record should be kept separate from its receptor pharmacology, trial outcomes, and analytical identity. The cagrilintide modification-mapping guide explains why disulfide connectivity, amidation, and lipidation require distinct checks.
Which study measured the half-life?
The randomized Phase 1b trial indexed by NIH PubMed (PMID 33894838) evaluated concomitant cagrilintide and semaglutide. It reported cagrilintide half-lives of 159–195 hours across the tested groups and median times to maximum concentration of 24–72 hours. These were pharmacokinetic observations in a controlled multiple-dose study, not specifications for commercial research material.
A public ClinicalTrials.gov protocol for NCT04982575 describes cagrilintide's half-life as approximately 180 hours. That rounded value falls within the published Phase 1b range.
| Evidence item | Reported observation | Correct interpretation |
|---|---|---|
| Phase 1b terminal half-life | 159–195 hours | Range observed across tested cagrilintide groups |
| Protocol summary | Approximately 180 hours | Rounded development-program value |
| Median time to maximum concentration | 24–72 hours | Time to measured peak, not half-life |
| Dose-proportional exposure | AUC and Cmax increased with dose | Does not mean every endpoint changes proportionally |
Why the number is a range
Half-life is derived from the terminal portion of a concentration-time profile. Different participants, sampling windows, dose groups, and curve fits can produce different estimates. Reporting 159–195 hours preserves the study's measured range; converting it to “about one week” is a useful summary but loses detail.
Time to maximum concentration is not interchangeable with half-life. A delayed peak describes absorption and distribution before the terminal decline. The half-life describes the slope after the terminal phase has been identified. Neither measurement, by itself, establishes receptor selectivity or an outcome.
What prolongs cagrilintide exposure?
Cagrilintide was engineered as a long-acting amylin analogue. The development paper indexed through NIH PubMed by DOI describes sequence engineering and fatty-diacid lipidation used to extend duration. Preclinical design evidence explains the rationale, while the human study supplies the measured pharmacokinetic value. Those are complementary evidence layers, not interchangeable proof.
The Cagrilintide research material page and lot-specific COA library support catalog and analytical record matching. They do not convert a clinical half-life into a batch specification. The same separation applies to CagriSema research material: coadministration or mixture records do not establish the disposition of each component without component-specific measurement.
For broader context, the cagrilintide clinical-trials guide separates monotherapy and CagriSema designs, while the CagriSema evidence guide explains why clinical coadministration does not validate every premixed blend. Related materials are organized in the GLP-1 peptide collection.
Research limitations
The published range comes from a defined clinical formulation, route, population, assay, and sampling schedule. It should not be assigned to a different molecular form, formulation, biological species, or laboratory matrix. The available value is a terminal pharmacokinetic estimate, not a dosing instruction, a complete-clearance time, or proof that a research vial matches the clinical material.
Frequently asked questions
What is cagrilintide's reported half-life?
The Phase 1b study reported 159–195 hours, approximately 6.6–8.1 days.
Why do some sources say 180 hours?
Approximately 180 hours is a rounded summary that sits within the published 159–195-hour range.
Is time to peak concentration the same as half-life?
No. Time to peak describes when the measured maximum occurs; half-life describes the later terminal decline.
Can a cagrilintide COA prove a one-week half-life?
No. A COA describes tested batch attributes. Half-life requires a biological concentration-time study.
NEXTWAVE PEPTIDES uses source-matched records so analytical, molecular, and clinical evidence remain distinct.